Aggiornamenti

IMI2-2018-16-01: Progress new assets (one pre-new molecular entity (preNME) and one first-time-in-human (FTIH) start) for TB that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors
IMI2-2018-16-02: Progress novel assets (one FTIH start) for non-tubercular mycobacteria (NTM) that may act synergistically with bedaquiline and cytochrome bc drugs
IMI2-2018-16-03: Discover and progress novel assets with new mechanisms of action (one preNME for TB and one preNME for NTM) and biomarkers for TB and NTM infection
IMI2-2018-16-04: Determination of gepotidacin levels in tonsils and prostatic tissue
IMI2-2018-16-05: Infection site targeting, antibiotic encapsulated in nanoparticles for treating extracellular bacterial infections
IMI2-2018-16-06: Functional Ethionamide boosters: a novel combination for tuberculosis therapy
IMI2-2018-16-07: Intravenous treatments of serious infections (urinary tract infections, intra-abdominal infections & hospital-acquired pneumonia/ventilator associated pneumonia) caused by Gram(-) bacteria (Enterobacteriaceae +/- Pseudomonas and/or Acinetobacter)
IMI2-2018-15-01: Integrated research platforms enabling patient-centric drug development
IMI2-2018-15-02: Blockchain Enabled Healthcare
IMI2-2018-15-03: Microenvironment imposed signatures in tissue and liquid biopsies in immune-mediated diseases
IMI2-2018-15-04: Emerging translational safety technologies and tools for interrogating human immuno-biology
IMI2-2018-15-05: Development and validation of translational platforms in support of synaptopathy drug discovery
IMI2-2018-15-06: Digital endpoints in neurodegenerative and immune-mediated diseases
IMI2-2018-15-07: AMR Accelerator programme Pillar A: Capability Building Network to accelerate and validate scientific discoveries
IMI2-2018-15-08: AMR Accelerator programme Pillar B: Tuberculosis drug development network to accelerate and validate scientific discoveries and advance the R&D pipeline of new and innovative agents to address the global tuberculosis epidemic
Bando Fabbrica Intelligente, Agrifood, Scienze della Vita
SC1-HCO-01-2018-2019-2020: Actions in support of the International Consortium for Personalised Medicine
SC1-BHC-28-2019: The Human Exposome Project: a toolbox for assessing and addressing the impact of environment on health
SC1-BHC-25-2019: Demonstration pilots for implementation of personalised medicine in healthcare
SC1-BHC-22-2019: Mental health in the workplace
SC1-BHC-19-2019: Implementation research for maternal and child health
SC1-BHC-14-2019: Stratified host-directed approaches to improve prevention, treatment and/or cure of infectious diseases
SC1-BHC-13-2019: Mining big data for early detection of infectious disease threats driven by climate change and other factors
SC1-BHC-10-2019: Innovation Procurement: Next generation sequencing (NGS) for routine diagnosis
SC1-BHC-07-2019: Regenerative medicine: from new insights to new applications
SC1-BHC-02-2019: Systems approaches for the discovery of combinatorial therapies for complex disorders
SC1-BHC-01-2019: Understanding causative mechanisms in co- and multimorbidities
SC1-HCC-02-2019: Support for the large scale uptake of open service platforms in the Active and Healthy Ageing domain
SC1-DTH-11-2019: Large Scale pilots of personalised & outcome based integrated care
SC1-DTH-10-2019-2020: Digital health and care services
SC1-DTH-09-2019: Scaling up the univocal Identification of Medicinal Products
SC1-DTH-05-2019: Large scale implementation of digital innovation for health and care in an ageing society
SC1-DTH-01-2019: Big data and Artificial Intelligence for monitoring health status and quality of life after the cancer treatment
Fast Track to Innovation (FTI)
IMI2-2018-14-01: Targeted immune intervention for the management of non-response and relapse
IMI2-2018-14-02: Non-invasive clinical molecular imaging of immune cells
IMI2-2018-14-03: Development of a platform for federated and privacy-preserving machine learning in support of drug discovery
IMI2-2018-14-04: Centre Of Excellence – Remote Decentralised Clinical Trials
PNR 2015-2020: Progetti di Ricerca di Proof of Concept
PON Ricerca & Innovazione 2014-2020: Fondo dei Fondi - Miur
PON Ricerca e Innovazione 2014-2020: Dottorati innovativi con caratterizzazione industriale - XXXIV Ciclo
IMI2 - call 13 - topic 1: Assessment of the uniqueness of diabetic cardiomyopathy relative to other forms of heart failure using unbiased pheno-mapping approaches
IMI2 -call 13 - topic 2: Genome-Environment Interactions in Inflammatory Skin Disease
IMI2 - call 13 - topic 3: The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use
IMI2 - call 13 - topic 4: Mitochondrial Dysfunction in Neurodegeneration
IMI2 - call 13 - topic 5: Support and coordination action for the projects in the neurodegeneration area of the Innovative Medicines Initiative
IMI2 - call 13 - topic 6: A sustainable European induced pluripotent stem cell platform
IMI2 - call 13 - topic 7: Linking digital assessment of mobility to clinical endpoints to support regulatory acceptance and clinical practice
IMI2 - call 13 - topic 8: Human tumour microenvironment immunoprofiling
IMI2 - call 13 - topic 9: ConcePTION – Continuum of Evidence from Pregnancy Exposures, Reproductive Toxicology and Breastfeeding to Improve Outcomes Now
IMI2 - call 13 - topic 10: Improving the preclinical prediction of adverse effects of pharmaceuticals on the nervous system
IMI2 - call 13 - topic 11: Translational Safety Biomarker Pipeline (TransBioLine): Enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease
IMI2 - call 13 - topic 12: Pilot programme on a Clinical Compound Bank for Repurposing: Cardiovascular diseases and diabetes
IMI2 - call 13 - topic 13: Pilot programme on a Clinical Compound Bank for Repurposing: Respiratory diseases
IMI2 - call 13 - topic 14: Pilot programme on a Clinical Compound Bank for Repurposing: Neurodegenerative diseases
IMI2 - call 13 - topic 15: Pilot programme on a Clinical Compound Bank for Repurposing: Rare/orphan diseases
Opportunità EUROPA
Opportunità ITALIA